{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(10)"],"submitter":["Baruchel A"],"pubmed_abstract":["Children with relapsed acute leukemia have a poor prognosis; current relapse treatments are toxic, and novel treatments are needed. The anti-CD38 antibody isatuximab is approved for relapsed-refractory multiple myeloma in adults. We present results of the ISAKIDS study (NCT03860844) investigating isatuximab in children with relapsed-refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). This Phase 2, single-arm, multicenter, open-label study enrolled children aged 28 days to <18 years. Patients received isatuximab 20 mg/kg induction on Day 1, then weekly for 5 weeks (ALL) or 3 weeks (AML). Standard salvage chemotherapy was added on Day 8. Participants showing possible response could receive consolidation with every-other-week isatuximab (two doses) plus chemotherapy"],"journal":["HemaSphere"],"pagination":["e70245"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12572944"],"repository":["biostudies-literature"],"pubmed_title":["Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study."],"pmcid":["PMC12572944"],"pubmed_authors":["Valera ET","Leverger G","Abbadessa G","Michalowski MB","Choque WQ","Freigeiro D","Cesaro S","Wang L","Fagioli F","Abrahamsson J","Nysom K","Epelman S","Gonzalez-Llano O","Mace S","Kang HJ","Buechner J","Zwaan CM","Kattamis A","Alarcon A","Nelken B","Oprea C","Felice MS","Duarte J","Baruchel A","Moreira L","Rizzari C","Lopes de Sousa AV"],"additional_accession":[]},"is_claimable":false,"name":"Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study.","description":"Children with relapsed acute leukemia have a poor prognosis; current relapse treatments are toxic, and novel treatments are needed. The anti-CD38 antibody isatuximab is approved for relapsed-refractory multiple myeloma in adults. We present results of the ISAKIDS study (NCT03860844) investigating isatuximab in children with relapsed-refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). This Phase 2, single-arm, multicenter, open-label study enrolled children aged 28 days to <18 years. Patients received isatuximab 20 mg/kg induction on Day 1, then weekly for 5 weeks (ALL) or 3 weeks (AML). Standard salvage chemotherapy was added on Day 8. Participants showing possible response could receive consolidation with every-other-week isatuximab (two doses) plus chemotherapy","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-05T11:34:05.406Z","creation":"2026-05-16T03:12:52.473Z"},"accession":"S-EPMC12572944","cross_references":{"pubmed":["41180900"],"doi":["10.1002/hem3.70245"]}}